Staphylococcus aureus bacteremia: the cost-effectiveness of long-term therapy associated with infectious diseases consultation

Clin Perform Qual Health Care. 1998 Jan-Mar;6(1):9-11.

Abstract

Objective: To investigate the cost-effectiveness of long-term therapy for Staphylococcus aureus bacteremia and to determine if an infectious diseases consultation affected the duration of therapy.

Methods: A decision analysis was performed based on data from the literature. To determine if consultation was related to therapy duration, a retrospective cohort study was performed using tightly matched pairs.

Results: The excess cost per life saved by long-term antibiotics was $500,000. The excess cost per life-year saved was $18,000. Nine pairs were matched. Patients who received consultation were more likely to receive long-term therapy than controls (median 41 days vs 15 days for controls, P = .04).

Conclusions: The estimated cost per life-year saved by long-term therapy was similar to other accepted medical interventions. Infectious diseases consultation can encourage prolonged duration of antibiotic therapy for S aureus bacteremia.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / economics*
  • Bacteremia / drug therapy
  • Bacteremia / economics*
  • Cost-Benefit Analysis
  • Decision Support Techniques*
  • Drug Costs
  • Female
  • Hospital Bed Capacity, 500 and over
  • Hospitals, Teaching / economics
  • Humans
  • Iowa
  • Male
  • Middle Aged
  • Referral and Consultation / economics*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / economics*
  • Staphylococcal Infections / mortality
  • Staphylococcus aureus*
  • Time Factors
  • Treatment Outcome
  • Value of Life*

Substances

  • Anti-Bacterial Agents